Lung cancer in 2014: Optimizing lung cancer treatment approaches

Nature Reviews Clinical Oncology

Volumn 12, Issue 2, 2015, Pages 75-76

  Rosell, Rafael ^a   Karachaliou, Niki ^b  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b INSTITUT UNIVERSITARI DEXEUS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; BEVACIZUMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FIBROBLAST GROWTH FACTOR; FLUORODEOXYGLUCOSE F 18; INTERLEUKIN 6; JANUS KINASE; NINTEDANIB; PLACEBO; RUXOLITINIB; STAT3 PROTEIN; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG EFFICACY; EGFR GENE; ETHNICITY; GENE EXPRESSION; GENE MUTATION; HUMAN; LUNG CANCER; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT SURVEY; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; LUNG NEOPLASMS; MOLECULARLY TARGETED THERAPY; MUTATION; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; PROTO ONCOGENE; SCINTISCANNING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; GENES, ERBB-1; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; MUTATION; POSITRON-EMISSION TOMOGRAPHY;

EID: 84961328429     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2014.225     Document Type: Short Survey

References (9)

1. Rosell, R., Bivona, T. G. & Karachaliou, N. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet 382, 720-731 (2013).
2. Lee, H. J. et al. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell 26, 207-221 (2014).
3. Gao, S. P. et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J. Clin. Invest. 117, 3846-3856 (2007).
4. Fan, W. et al. MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents. Cancer Res. 71, 4494-4505 (2011).
5. 18F]FDG positron emission tomography within two weeks of starting erlotinib therapy can predict response in non-small cell lung cancer patients. PLoS ONE 9, e87629 (2014).
6. Seto, T. et al. Erlotinib alone or with bevacizumab as a first line therapy in patients with advanced non-squamous non-small cell lung cancer harbouring epidermal growth factor receptor mutations (JO25567): a randomised phase II study. Lancet Oncol. 15, 1236-1244 (2014).
7. Li, R. et al. Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer. Mol. Cancer Ther. 12, 2200-2212 (2013).
8. Reck, M. et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 15, 143-155 (2014).
9. Moran, T. et al. Two biomarker-directed randomized trials in European and Chinese patients with non-small-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies. Ann. Oncol. 25, 2147-2155 (2014).